In addition, strategies could aim to stimulate activation and tumor infiltration of immune cells which are known to produce or activate TGFβ, such as monocytes or macrophages [83], in conjunction with concurrent targeted therapy. This evidence concerns the gene TGFB1 and neoplasm.